Skip to main content

DMARD Monitoring: Link Disease Activity, Lab Trends and Refill Review

A DMARD follow-up record needs two linked assessments: how the inflammatory disease is behaving and whether the current medicine plan remains appropriate and safe. Keep the disease-activity score, drug-specific monitoring plan, dated laboratory trends and prescribing decision distinct. A reassuring symptom report or a laboratory upload alone must not automatically authorise the next prescription.

By Bractis · Updated · 9 min read

Rheumatologists, physicians and Indian clinics coordinating conventional disease-modifying antirheumatic drugs, outside laboratories and shared follow-up.

Separate disease control from medicine monitoring

A patient can describe improved pain while an outstanding laboratory result still requires review. Conversely, available safety tests do not establish that inflammatory disease is controlled. Build the encounter around both questions so that one completed checklist cannot conceal unfinished work in the other.

Record symptoms, functional changes, examination findings and the clinician's assessment of disease activity in one part of the note. Keep medicine identity, actual use, relevant new symptoms, monitoring evidence and the prescribing decision in another. Link them through a dated assessment rather than a single 'stable' checkbox.

NICE's adult rheumatoid-arthritis guidance uses disease-activity assessment alongside inflammatory markers within specialist care. It provides context for keeping those data together, but it does not turn a score into a substitute for the rest of the consultation or supply an Indian clinic's medicine-monitoring schedule.

Use the patient's own practical goals where possible: opening a container, returning to work or managing a morning routine. Record whether a change is reported by the patient, observed during assessment or inferred by the clinician. This makes longitudinal improvement more interpretable than repeatedly copying a generic 'better' label.

Source: NICE NG100: Rheumatoid arthritis in adults — management

Make a DAS28 entry reproducible without inventing missing inputs

Store the named score variant and the evidence used to produce it. A DAS28 entry should identify the assessment date, examiner, joint-count inputs, the inflammatory marker and its specimen date, and any other inputs required by that particular validated method. Retain the calculator or method version used by the service.

NICE's linked evidence review discusses ESR- and CRP-based DAS28 variants. Their names matter in a longitudinal chart: a bare 'DAS28' field can conceal a change in the underlying method. If a clinic changes method, label the transition so the doctor can decide how to compare the results.

An unexamined joint or a missing patient assessment is not a zero. A result from an old laboratory sample should not appear to have been measured on the examination date. If the required inputs are unavailable, preserve the partial assessment and state why the score was not calculated.

Do not use a calculator to manufacture a diagnosis or a treatment decision. The purpose of storing inputs is to let the treating clinician verify the score and place it in context, including symptoms or joints not represented adequately by that one measure.

On a narrow screen, scroll the table horizontally to read all columns.

Three different forms of evidence in a rheumatology review
EvidenceRequired contextWhat it does not establish alone
Disease-activity scoreVariant, complete inputs, examiner and relevant datesThat the current medicine is safe to continue
Laboratory monitoringSpecimen date, units, trend and clinician reviewThat disease activity is controlled
Patient-reported functionSpecific activity, baseline and sourceA complete objective examination
Medicine reconciliationExact product, regimen and actual useThat a prescription was taken as intended
Prescription decisionResponsible clinician, date and follow-up conditionsThat every pending task has been completed

Source: NICE NG100: Rheumatoid arthritis in adults — management

Keep the monitoring plan specific to the medicine and the patient

The 2025 British Society for Rheumatology guideline addresses conventional synthetic DMARD prescribing and monitoring and supersedes its 2017 predecessor. Its risk-based approach is a reason to identify the applicable guideline and the patient's circumstances explicitly, rather than paste one fixed interval into every DMARD record.

The NHS Specialist Pharmacy Service methotrexate page, updated in January 2026, states that alignment with the newer BSR guideline is pending. A clinic should not copy an interval from that page while describing it as an implementation of the newer guideline. Document the reference actually used and the clinician who approved the local plan.

For each medicine, record the indication, dose and frequency as authorised, relevant start or change date, required investigations, planned review points and the clinician responsible for interpreting results. A combination regimen may require several considerations; a single 'DMARD bloods' label can obscure them.

The treating team decides how renal or hepatic disease, other medicines, intercurrent illness and other individual factors affect monitoring. This article does not prescribe a test panel or interval. It provides a place to preserve that decision, its rationale and the date at which it should be reconsidered.

When the plan changes, retain the old version as history and make the current version unambiguous. An automated reminder based on a superseded interval should be reviewed, not allowed to continue merely because it was scheduled earlier.

Source: British Society for Rheumatology: 2025 csDMARD prescribing and monitoring guideline

Source: NHS Specialist Pharmacy Service: Methotrexate monitoring

Treat refill review as a clinical handover

Establish who is prescribing, who is arranging tests and who reviews them when care is shared between a rheumatologist and a local physician. Record the agreed coverage route during leave or travel. 'Specialist follow-up advised' is not a clear assignment of the next result.

Reconcile actual medicine use, including interruptions, changed brands or strengths and instructions received elsewhere. For a once-weekly medicine, retain the prescribed weekday and frequency explicitly and link to the separate weekly-medicine teaching record. A refill quantity cannot prove that every dose was taken.

If results or a specialist opinion are unavailable when the patient requests a prescription, route the unresolved question to the responsible clinician. Staff should neither issue automatic clinical clearance nor invent a blanket withholding instruction. The clinician's interim decision, patient communication and outstanding work must be attributable.

After the decision, record what was authorised, from which date and under what follow-up conditions. If the patient receives a changed plan by telephone, capture who communicated it and whether the patient understood which previous instruction it replaces. Keep prescription status separate from laboratory task status.

Shared-care correspondence should include enough detail for the receiving clinician to act: current regimen, recent changes, relevant results, outstanding questions and the next responsible person. A long attachment with no explicit request can leave everyone assuming another team will act.

Make the next review understandable in one page

The handover below is intended to accompany, not replace, the consultation and original results. It makes uncertainty visible and helps a covering doctor identify what needs a decision.

During a record review, choose a fictional case where symptoms improved but one monitoring result is outstanding. Check that the system can show those two facts at the same time. A workflow that permits only 'complete' or 'incomplete' for the whole visit may hide the distinction.

Improvement and an unfinished safety review can coexist

A fictional patient reports being able to dress more easily and has a completed joint assessment. The receptionist has uploaded one laboratory report, but a separate investigation requested by the clinician is still outstanding. The record preserves the improved function and the incomplete evidence without marking the entire medicine review as cleared. The responsible clinician makes and documents the prescription decision, assigns follow-up of the missing result and tells the patient what happens next. The software does not infer the decision from the activity score.

DMARD review handover

Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.

Two assessments
Where can the next doctor distinguish disease control from medicine safety and see the evidence for each?
Score identity
Are the score variant, complete inputs and dates visible, with missing data left missing?
Plan version
Which drug-specific reference and patient circumstances informed the current monitoring plan, and who approved it?
Shared responsibility
Who reviews each outstanding result, authorises prescriptions and covers absence?

Questions doctors ask

Does a low disease-activity score clear a DMARD refill?

No. Disease activity and medicine monitoring answer different questions. The prescribing clinician needs the relevant clinical assessment, actual medicine use and monitoring evidence before making an attributable decision.

Can missing DAS28 inputs be recorded as zero?

No. Preserve the incomplete assessment and identify the missing input. Only calculate a named score when the required information for that validated method is available.

Can every DMARD use the same blood-test schedule?

A universal schedule can conceal differences in medicine, treatment stage and individual risk. Record the drug-specific plan authorised by the treating team, including its reference and version.

Why keep trends if a laboratory marks each result normal?

A flag is only one part of the evidence. The clinician may need the sequence, units, laboratory context and clinical changes to assess a trend; the software should show them without generating its own treatment instruction.

What should reception do when a refill request arrives before a result?

Identify exactly what is missing and route the question to the responsible clinician or agreed cover. Record the clinician's decision and follow-up; do not convert a missing result into an automatic approval or an invented medicine-stop rule.

Sources and scope

Updated on . This guide concerns documentation and continuity for clinician-led care. It does not calculate DAS28, choose a DMARD, prescribe monitoring intervals or provide medicine hold/restart thresholds. UK references are identified as such. No independent clinical or legal review is claimed.

Try the workflow
with Bractis.

Walk through a fictional DMARD review with a complete activity assessment and one outstanding result. Inspect score provenance, monitoring-plan versions and the clinician's prescription decision.

Request a clinic demo